acadia pharmaceuticals inc
(ACAD:NASDAQ GM)

Last $13.79 USD

Change Today -0.36 / -2.54%

Volume 3.4M

ACAD On Other Exchanges

Symbol

Exchange

ACAD:US

NASDAQ GM

ACU:GR

As of 5:20 PM 05/21/13 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements Ratios Pensions & Options SEC Filings

Financial Statements for acadia pharmaceuticals inc (ACAD)

Year over year, ACADIA Pharmaceuticals Inc. has been able to grow revenues from $2.1M USD to $4.9M USD. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold from 571.41% to 271.71%. This was a driver that led to an improvement in the bottom line from a loss of $22.8M USD to a smaller loss of $20.8M USD.

Income Statement Balance Sheet Cash Flow

Currency in Millions of US Dollars	As of:	Dec 31 2009 Reclassified	Dec 31 2010 Reclassified	Dec 31 2011	Dec 31 2012	4 Year Trend
Revenues		6.4	42.1	2.1	4.9
TOTAL REVENUES		6.4	42.1	2.1	4.9
Cost of Goods Sold		27.9	13.6	11.8	13.3
GROSS PROFIT		-21.5	28.5	-9.7	-8.4
Selling General & Admin Expenses, Total		10.3	6.5	7.6	7.0
R&D Expenses		12.8	7.0	5.5	5.5
OTHER OPERATING EXPENSES, TOTAL		23.1	13.4	13.1	12.5
OPERATING INCOME		-44.6	15.1	-22.9	-20.9
Interest and Investment Income		0.3	0.0	0.1	0.0
Merger & Restructuring Charges		-0.9	--	--	--
EBT, INCLUDING UNUSUAL ITEMS		-45.1	15.1	-22.8	-20.8
Earnings from Continuing Operations		-45.1	15.1	-22.8	-20.8
NET INCOME		-45.1	15.1	-22.8	-20.8
NET INCOME TO COMMON INCLUDING EXTRA ITEMS		-45.1	15.1	-22.8	-20.8
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS		-45.1	15.1	-22.8	-20.8